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The association between administration of unfractionated 
heparin sodium (UFH) and elevations in serum aminotrans-
ferases was first reported more than 25 years ago, and subsequent 
studies have validated this association.1–4 Further case reports 
and clinical studies have indicated that this property is not unique 
to UFH and that similar aminotransferase elevations occur after 
administration of low-molecular-weight heparin products.5–7 
These elevations in serum aminotransferases are characteristically 
asymptomatic and reverse with continued treatment;8 serious 
liver injury due to heparins has not been reported.5 Accordingly, 
there are currently no guidelines requiring the monitoring of 
liver parameters in patients on any heparin therapy.9
Adomiparin sodium (adomiparin),10,11 a novel, rationally 
designed low-molecular-weight heparin, is currently under 
evaluation for the treatment of acute coronary syndrome 
(ACS). Early clinical studies indicated an unexpectedly high 
incidence and magnitude of ALT elevations associated with the 
use of this compound. However, there is little published infor-
mation regarding the time course, magnitude, and incidence 
of aminotransferase elevations when heparins are used to treat 
ACS, which necessitates relatively high daily doses adminis-
tered over several days. To compare the effects of adomiparin 
on the liver relative to the effects of currently approved heparin 
products, we conducted a phase I, randomized study in healthy 
volunteers.
Although the primary objective of the study was to compare 
the time-dependent incidence and magnitude of serum ami-
notransferase levels across treatments with UFH, enoxaparin, 
dalteparin, and adomiparin administered at doses typically used 
in ACS, the study also provided an opportunity to utilize addi-
tional biomarkers to gain insight into the mechanisms underly-
ing these effects.
Results
A total of 48 healthy men 19–49 years of age were enrolled in 
the study and randomly assigned to receive UFH, dalteparin, 
enoxaparin, or adomiparin twice daily for 4 consecutive days 
plus the morning of the fifth day (a total of nine doses). All data 
obtained for each subject are listed in Supplementary Table S1 
online.
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Heparins have been reported to cause elevations in serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) but have not been associated with clinically significant liver injury. The mechanisms underlying 
these benign laboratory abnormalities are unknown. Forty-eight healthy men were randomized to receive subcutaneous 
injections of unfractionated heparin (UFH; 150 U/kg), enoxaparin sodium (1 mg/kg), dalteparin sodium (120 IU/kg), or 
adomiparin sodium (125 IU/kg; a novel heparin) every 12 h for 4.5 days. Asymptomatic elevations in serum ALT or AST 
were observed in >90% of the subjects. Elevations were also observed in the levels of serum sorbitol dehydrogenase 
(SDH), glutamate dehydrogenase (GLDH), miR-122, high-mobility group box-1 protein (including the acetylated form), 
full-length keratin 18, and DNA. Keratin 18 fragments, which are apoptosis biomarkers, were not detected. Biomarker 
profiles did not differ significantly across heparin treatments. We conclude that heparins as a class cause self-limited  
and mild hepatocyte necrosis with secondary activation of an innate immune response.
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Aminotransferase elevations
Treatment-emergent elevations in serum alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) values above 
the upper limits of normal were observed in 94% (45/48) and 
90% (43/48) of the subjects, respectively. During each of the 
treatments, the values generally began to rise by day 3, reach-
ing their peaks on day 7, 2 days after the end of the heparin 
course (Figure 1, AST data not shown). There were no signifi-
cant intergroup differences in ALT or AST values at any of the 
time points tested (P < 0.05). The mean peak values of ALT and 
AST, expressed as multiples of the upper limit of normal, were 
3.4 ± 0.4 and 2.1 ± 0.2 (mean ± SEM), respectively.
Episodes of grade 3 increases in ALT (exceeding five times 
the upper limits of normal) were reported in 11 subjects (23%) 
across all the treatment groups (Table 1). All the elevated ALT 
and AST values returned to the reference range. No grade 4 
elevations were noted; however, in one subject treated with 
dalteparin, the peak ALT value was 13 times the upper limit of 
normal (Figure 1b). The duration of the ALT elevation outside 
the reference range varied from ~2 days to 33 days. None of the 
subjects experienced clinical signs of liver injury (i.e., no fatigue, 
nausea, or right-upper-quadrant pain was reported).
The mean alkaline phosphatase (ALP) values remained 
within the reference range (47–132 U/l) with minimal changes 
for all treatments at all time points. Bilirubin values were not 
observed to deviate from the reference range (0.3–1.6 mg/dl) 
throughout the study. AST, ALP, and bilirubin values are shown 
in Supplementary Table S1 online.
Additional protein biomarker analysis
With the exception of the cleaved form of keratin 18 (K18), treat-
ment-emergent elevations were observed in each of the additional 
serum proteins measured: sorbitol dehydrogenase (SDH), gluta-
mate dehydrogenase (GLDH), full-length K18 (Figure 2d), and 
high-mobility group box-1 protein (HMGB1; Figure 3a). The 
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Figure 1 serum alanine aminotransferase (aLt) levels in each study subject before, during, and after twice-daily subcutaneous injections of (a) unfractionated 
heparin (150 U/kg), (b) dalteparin sodium (120 IU/kg), (c) enoxaparin sodium (1 mg/kg), and (d) adomiparin sodium (125 IU/kg). the subjects received the first 
dose on the morning of day 1 and the final dose on the morning of day 5. the upper limit of the normal reference range is denoted by the dotted line. ULN, 
upper limit of normal.
table 1 WHO toxicity grades for Ast and Alt results by treatment
Toxicity grade
Treatment
ALT (n = 48) AST (n = 48)
UFH Enoxaparin Dalteparin Adomiparin UFH Enoxaparin Dalteparin Adomiparin
grade 0 (within normal limits) 2 0 0 1 3 0 1 1
grade 1 (>ULN–2.5 × ULN) 5 5 5 4 5 6 5 4
grade 2 (>2.5–5.0 × ULN) 4 4 4 3 4 4 4 4
grade 3 (>5.0–20.0 × ULN) 1 3 3 4 0 2 2 3
grade 4 (>20.0 × ULN) 0 0 0 0 0 0 0 0
aLt, alanine aminotransferase; ast, aspartate aminotransferase; UFH, unfractionated heparin; ULN, upper limit of normal (of reference range); WHO, World Health Organization.
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mean values were generally attained on day 7, tracking generally 
well with the course of elevations in ALT and AST (Table 2). The 
Pearson correlation coefficient (σ) of ALT levels for all treatments 
with protein biomarkers at the peak elevation (day 7) was 0.91 
with SDH, 0.76 for GLDH, 0.76 for HMGB1, and 0.93 for full-
length K18. As was observed with aminotransferase elevations, 
there were no intergroup differences for any pair of heparin treat-
ments in the magnitude of increase in each of the serum biomar-
ker levels at any of the time points tested (P < 0.05).
With total HMGB1, the mean serum value at day 5 (the last day 
of heparin treatment) across all treatments was higher than on day 
6 (P < 0.05). This “double peaking” in HMGB1 was noted in 31 of 
the 48 subjects (65%) and was not evident with the other protein 
biomarkers (see Supplementary Table S1 online). During the 
first peak, circulating HMGB1 was not detectably acetylated, but 
during the second peak, 20–35% of the HMGB1was acetylated 
(Figure 4). We observed no time-dependent changes in any of the 
treatments with respect to the circulating levels of cleaved K18, a 
marker for epithelial cell apoptosis (Figure 2c).
DNA analysis
The levels of DNA were measured using PicoGreen assay in 
plasma samples obtained before the first heparin dose on day 1 
and again in plasma samples obtained on day 5, corresponding 
to the first peak in HMGB1 levels in serum. The mean DNA 
levels rose between days 1 and 5 for each of the four heparin 
treatments, with the increase being significant for enoxaparin 
and adomiparin (P < 0.05). When data from all the treatment 
arms were combined, the mean plasma DNA level rose from 
the baseline level of 824.7 ± 21.2 ng/ml before treatment on day 
1 to 941.1 ± 19.1 ng/ml on day 5 (P < 0.0001, mean ± SEM; see 
Supplementary Table S1 online).
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Figure 2 serum measurements of liver injury biomarkers (a) sorbitol dehydrogenase (sDH); (b) glutamate dehydrogenase (gLDH); and biomarkers of cellular 
injury modality, including (c) cleaved keratin 18 (cleaved K18) and (d) full-length keratin 18 (K18); are depicted as mean values ± sEM. the subjects received the 
first dose on the morning of day 1 and the final dose on the morning of day 5. the upper limit of the normal reference range or the average (avg.) baseline value 
is denoted by the dotted line. Unfractionated heparin (filled circles), enoxaparin sodium (open squares), dalteparin sodium (filled triangles), and adomiparin 
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Figure 3 serum measurements of (a) the cellular necrosis biomarker, high-
mobility group box-1 protein (HMgB1), and (b) hepatocyte injury biomarker 
miR-122 are depicted as the mean value ± sEM for each treatment. the subjects 
received the first dose on the morning of day 1 and the final dose on the 
morning of day 5. the upper limit of the normal reference range or the average 
(avg.) baseline value is denoted by the dotted line. Unfractionated heparin 
(filled circles), enoxaparin sodium (open squares), dalteparin sodium (filled 
triangles), and adomiparin sodium (filled squares). ULN, upper limit of normal.
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miR-122 analysis
Coincident with elevations in liver enzymes, miR-122 levels in 
the serum were also elevated after heparin treatment (Figure 3b). 
There were no significant intergroup differences in the serum 
levels of miR-122 at any of the measured time points, including 
on day 7 when the peak elevation occurred. The levels of miR-
122 exhibited a larger dynamic range than those of the protein 
biomarkers measured. In 15 subjects (31%), the miR-122 value 
rose >20-fold relative to the baseline value (3 in UFH arm, 1 in 
the dalteparin arm, 4 in the enoxaparin arm, and 7 in the adomi-
parin arm). As with HMGB1, the serum miR-122 level was often 
higher on day 5 than on day 6, with “double peaking” evident in 
26 of the 48 subjects (~54%), although the mean values were not 
statistically different between the two days (P >0.05).
DiscussiON
Consistent with previous reports, elevations in serum ALT and 
AST levels were observed during treatment with UFH and with 
all the low-molecular-weight heparin preparations. However, the 
frequency and magnitude of heparin-induced aminotransferase 
elevations were considerably higher in this study than in those 
previously reported. This is probably because this study used 
higher heparin doses that are typically used for the treatment 
of ACS. In addition, the majority of the published clinical stud-
ies on heparin treatment for other indications (i.e., deep-vein 
thrombosis) have not systematically measured liver chemistry 
parameters daily during the first week of treatment, possibly 
leading to underreporting of aminotransferase elevations.
The time course of aminotransferase elevations was consist-
ent across the various heparin treatment arms, beginning at 3 
days after the initiation of dosing in all groups, attaining peak 
values 24–48 h after cessation of dosing and generally returning 
to normal values within 1 week of discontinuing treatment.
The elevations in serum ALT and AST were asymptomatic 
and not associated with increases in bilirubin that would sug-
gest impairment of liver function. Nonetheless, the magnitude 
of the elevations observed in some subjects would prompt con-
cern regarding liver safety in most clinical settings and might 
be sufficient to initiate an extensive liver evaluation. In a phase 
I clinical trial of a new drug, such elevations might prompt dis-
continuation of development of the drug. Given that heparins 
have not been reported to cause clinically important liver injury, 
it has been suggested that the ALT and AST elevations in this 
setting may not reflect liver injury. The mechanisms postulated 
include nonhepatic sources for the enzymes,12 induction of 
these enzymes in hepatocytes,13 reduction in the clearance of 
these enzymes from circulation, and hepatocellular membrane 
modification.14,15 The mechanisms cannot be studied in rodents 
or dogs because these animals do not exhibit aminotransferase 
elevations when treated with heparins; in fact, heparins have 
been shown to mitigate liver injury in some rat models of liver 
injury.16,17 The clinical trial provided an opportunity for addi-
tional biomarker analyses in order to gain some mechanistic 
insight into heparin-related elevations in aminotransferases.
Circulating miR-122 originates only from the liver,18 and 
recent studies have utilized miR-122 detection as a biomarker of 
table 2 Pearson correlation coefficients between Alt and liver 
biomarker values in serum
Study day
1 4 5 6 7 12
gLDH 0.43 0.85 0.86 0.76 0.76 0.64
sDH 0.53 0.95 0.95 0.89 0.91 0.47
total HMgB1 0.16 0.29 0.59 0.85 0.76 0.82
Cleaved K18 0.24 0.67 0.44 0.21 0.38 0.17
Full-length K18 0.21 0.88 0.95 0.94 0.93 0.71
miR-122 0.63 0.54 0.29 0.60 0.59 0.14
aLt, alanine aminotransferase; gLDH, glutamate dehydrogenase; HMgB1, high-
mobility group box-1 protein; K18, keratin 18; sDH, sorbitol dehydrogenase.
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Figure 4 acetylation of high-mobility group box-1 protein (HMgB1) at 
baseline (day 1) and during the first peak (day 5) and second peak (day 7). 
the values, expressed as (a) multiples of baseline value, (b) multiples of ULN, 
and (c) percentage of total HMgB1, are depicted as the mean value ± sEM 
for each treatment. In this assay, the upper limit of normal was 0.12 ng/ml 
and the mean values obtained during the second peak were 1–2 ng/ml. UFH, 
unfractionated heparin; ULN, upper limit of normal.
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clinical acetaminophen-induced hepatotoxicity.19 The observed 
elevations in miR-122 in this study confirm a hepatic source for 
the biomarkers measured. The elevations in diverse liver-derived 
proteins and a microRNA species make it unlikely that induction 
or reduced plasma clearance are the mechanisms for the serum 
aminotransferase elevations seen in our study. We conclude that 
the elevations in serum biomarkers that we observed reflect a 
general leakage of hepatocellular contents.
Although it remains possible that the biomarkers entered the 
blood through physiological mechanisms, such as increased 
shedding of plasma membrane microvesicles,20 the observed 
elevations in GLDH make this less likely. GLDH is a large pro-
tein found in the liver and, to a lesser extent, in the kidney, where 
it is localized to the mitochondrial matrix;21 its entry into blood 
should reflect loss of mitochondrial membrane integrity or the 
entry of whole mitochondria into the blood, as could occur in 
necrosis or apoptosis.22 The absence of a rise in K18 fragments 
does not support the hypothesis of hepatocyte apoptosis,23 
making hepatocyte death by necrosis a more likely process to 
account for our observations. This is plausible, given that high 
concentrations of heparins have been shown to cause necrosis 
of primary rat hepatocytes in culture.24
It is also informative that all the biomarkers measured 
attained peak mean values almost 2 days after the last dose of 
each heparin treatment, and higher values might have been 
observed had serum samples been available between days 7 
and 12. Heparins have half-lives in the range of 2–6 h, and, 
even with subcutaneous injection, there should be negligible 
circulating concentrations of heparins at the time point when 
hepatocyte leakage appeared to be maximal. This suggests an 
indirect effect on the hepatocytes. In addition, the “double peak-
ing” frequently observed with respect to HMGB1 and miR-122 
in this study may suggest both a direct and an indirect effect 
of the heparins. The fall in mean levels of HMGB1 and miR-
122 at day 6 relative to day 5 is consistent with a direct effect 
of heparins on hepatocytes. HMGB1 is a known damage-as-
sociated molecular pattern released from necrotic cells that is 
capable of bridging cell death to the inflammatory response. 
HMGB1 binds to Toll-like receptors and to the receptor for 
advanced glycation end products, thereby initiating an innate 
immune response.25 The immune activation by HMGB1 may 
require cofactors, and mammalian DNA has been proposed as 
a potential cofactor.26 It may therefore be important that we 
observed a mean increase in circulating DNA at the time of the 
initial peak in serum HMGB1. Consistent with immune activa-
tion, we found that the secondary rise in HMGB1, but not the 
initial one, was associated with substantial acetylation of the 
protein. Although a recent report suggests that acetylation of 
HMGB1 may occur in hepatocytes during ischemia/reperfusion 
injury,27 acetylation is typically attributed to release of HMGB1 
from activated innate immune cells (e.g., Kupffer cells). Our data 
are therefore consistent with secondary activation of an innate 
immune response that could be linked to repair of the injury. 
However, the temporal link between acetylation of HMGB1 
and the second peaks in serum HMGB1 and miR-122 support 
the idea that the innate immune response might contribute to 
progression of liver injury (as indicated by the other biomarkers) 
for at least 2 days after the last dose of heparin. The absence of 
double peaking in biomarkers other than HMGB1 and miR-
122 may reflect the longer serum half-lives of these proteins. To 
our knowledge, the serum half-lives of HMGB1 and miR-122 
are not known in humans; however, data from one study that 
investigated acetaminophen-induced liver toxicity in rodents 
suggested that the serum HMGB1 derived from necrotic cell 
death has a half-life shorter than that of ALT activity.28 A recent 
investigation showed that, following acetaminophen hepatotox-
icity in humans, miR-122 also appears to have a shorter half-life 
than ALT.19
Why hepatocyte necrosis resolves despite continued heparin 
treatment8 and essentially never progresses to clinically impor-
tant liver injury is a fascinating question. Recent studies suggest 
that adaptive immune responses may be critical in the progres-
sion of at least some forms of drug-induced liver injury.29,30 
Heparins appear to cause transient hepatocyte necrosis and acti-
vation of an innate immune response; these effects may never 
elicit an adaptive immune response. We speculate that this may 
be because heparins are biological molecules that do not form 
the reactive metabolites that may be required for neoantigen 
formation. However, other biological agents have been associ-
ated with serious liver injury.31,32
In a clinical trial of a new drug, it is not currently possible to 
distinguish isolated elevations in serum ALT and AST that por-
tend serious liver injury potential (e.g., during treatment with 
isoniazid for tuberculosis) from transient and benign eleva-
tions that can occur during treatment with some generally safe 
drugs (e.g., statins, tacrine, aspirin, and heparins).33 A current 
US Food and Drug Administration guidance on assessing liver 
safety in clinical trials (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM174090.pdf) recommends continuing the treatment of 
subjects with asymptomatic elevations in ALT or AST to deter-
mine whether they go on to develop symptoms or signs of liver 
dysfunction (e.g., elevation of serum bilirubin). Because liver 
injury can progress quickly and continue after discontinuation 
of drug therapy, this practice may place some subjects at risk. 
There are now large-scale efforts, such as SAFE-T in Europe 
(http://www.imi-safe-t.eu/biomarker/drug-induced-injury/imi), 
that seek to identify new biomarkers that can help in interpret-
ing the significance of isolated elevations in serum ALT and 
AST. Prior to our study, it might have been assumed that the 
ideal biomarkers would be those capable of identifying hepato-
cyte necrosis and/or activation of innate immunity. Although 
we believe that the assays we utilized in our study will be useful 
in clinical trials, the interpretation of the data obtained in terms 
of liver safety risk may not be straightforward.
In summary, the four heparins we studied produced essentially 
indistinguishable elevations in a variety of hepatocyte biomark-
ers, indicating a class effect that most likely represents transient, 
low-level necrotic death of hepatocytes. Our data suggest that 
this necrotic death activates an innate immune response that 
may act to propagate the injury. Why this chain of events has 
no consequences for patients treated with heparins is a question 
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that remains unexplained by our data. Our findings have impli-
cations for the search for improved biomarkers of drug-induced 
liver injury.
MetHODs
study participants. A total of 48 healthy men (18–50 years of age) were 
enrolled in June and July of 2009 in accordance with the guidelines of 
the MDS Pharma Services Institutional Review Board, an entity that 
functions independently of MDS Pharma Services (Tempe, AZ). All 
procedures were in accordance with the principles enunciated in the 
Declaration of Helsinki (Seoul, 2008). Written informed consent was 
obtained from all subjects prior to the study. All subjects completed the 
clinical phase of the study, with none withdrawing or discontinuing.
Twelve subjects per drug treatment was expected to be sufficient to 
obtain adequate characterization of the relevant safety parameters under 
investigation in healthy adult subjects and to provide data for the primary 
end points of the study, namely, determination of the class effects for 
aminotransferase elevation and antibody formation across a variety of 
heparin compounds.
study design and procedures. This single-center, randomized, 
 double-blind, parallel-group phase I study was designed and con-
ducted at MDS Pharma Services.
At the enrollment visit (day 1), the subjects were asked to report 
to the study unit at least 15 h before the first scheduled dose. After 
check-in,  eligible subjects were randomly assigned to four groups of 
12 subjects each to receive twice-daily subcutaneous injections of one 
of the  following drugs: UFH (150 U/kg; Heparin Sodium Injection, 
USP, 20,000 U/ml; APP Pharmaceuticals, Schaumburg, IL), enoxaparin 
sodium (1 mg/kg; Lovenox; Sanofi-Aventis, Bridgewater, NJ), dalteparin 
sodium (120 IU/kg; Fragmin; Pfizer for Eisai, New York, NY), or adomi-
parin sodium (125 IU/kg; Momenta Pharmaceuticals, Cambridge, MA). 
The doses selected were those appropriate for the indication of ACS. The 
first dose was given on the morning of day 1, and the final dose was given 
on the morning of day 5. The subjects were confined to the clinic from at 
least 15 h before the first scheduled dose to 48 h after the last dose; that 
is, the subjects entered the clinic by the evening of day –1 and were dis-
charged on the morning of day 7.  Subjects returned for a follow-up visit 
7 days after the last dose (i.e., on day 12), and for a final safety evaluation 
to test for the development of heparin-induced antibodies 28 days after 
the last dose (i.e., day 33; data not shown).
While the subjects were confined in the clinic (from day −1 to day 7), 
standard meals were served at appropriate times throughout the day. Sub-
jects were required to fast overnight for at least 10 h before the morning 
dose on days 1 and 5 and were fasted for 4 prior to dosing on days 2-4. For 
the evening doses, subjects were required to fast from 2 h before until 2 h 
after dosing. Subjects were not permitted to drink water from 1 h before 
until 1 h after each dosing but was allowed at all other times.
Biomarker measurements. The primary end points with respect to 
safety were routine liver chemistry tests in serum samples collected 
before dosing on day 1 (baseline), before each morning dose on days 
2–5, at the same time in the morning on days 6 and 7, and at the 
follow-up visit on day 12. The samples were allowed to clot at room 
temperature for at least 30 min before refrigeration and centrifuga-
tion. Serum and plasma were stored at approximately −80 °C pending 
analysis. Clinical liver chemistry tests, including those for ALT, AST, 
ALP, and bilirubin, were performed by a commercial clinical labora-
tory (MDS Pharma Services). An additional primary end point—the 
potential occurrence of heparin/platelet factor 4 antibodies—is not 
within the scope of this article.
GLDH levels were determined in serum by means of an absorb-
ance assay using a glutamate dehydrogenase (DGKC) kit (Randox 
Laboratories, Kearneysville, WV) to measure the decrease in absorb-
ance caused by the oxidation of nicotinamide adenine dinucleotide at 
340 nm, per the manufacturer’s protocol. SDH levels were determined in 
serum by means of an absorbance assay using a sorbitol dehydrogenase 
kit (Genzyme Diagnostics, Cambridge, MA) to measure the decrease in 
absorbance caused by the oxidation of nicotinamide adenine dinucleotide 
at 340 nm, per the manufacturer’s protocol. Assay results for both GLDH 
and SDH were quantified using Cobas Fara II (Roche Diagnostics, Indi-
anapolis, IN). Total HMGB1 content was determined in serum by means 
of enzyme-linked immunosorbent assay (ELISA) per the manufacturer’s 
protocol (IBL International, Hamburg, Germany). Acetylated HMGB1 
was quantified using liquid chromatography–electrospray tandem mass 
spectrometry as described previously.34 Caspase-cleaved and total K18 
were determined using the M65 and M30 (apoptosense) ELISAs, respec-
tively, in accordance with the manufacturer’s guidelines (Peviva, West 
Chester, OH). For all ELISA analytes, the inter- and intra-assay vari-
abilities were <20% for all the assays.
DNA quantification. DNA was quantified in plasma samples taken from 
study subjects before the first dose on day 1 and on day 5. DNA was 
quantified using the Quant-iT PicoGreen dsDNA kit (Invitrogen, St 
Louis, MO) in accordance with the manufacturer’s recommendation; 
this assay primarily detects double-stranded DNA. Briefly, individual 
plasma samples in triplicate were diluted 50-fold in Tris-EDTA buffer 
(to a final concentration of 10 mmol/l Tris-HCl, 1 mmol/l EDTA, pH 
7.5); standard double-stranded DNA solutions were diluted in Tris-
EDTA buffer in accordance with the relevant protocols. The samples 
were incubated with Quant-it PicoGreen reagent, and fluorescence 
was quantified using a fluorescence microplate reader with excita-
tion wavelength at 485 nm and emission wavelength at 520 nm. The 
concentrations in the samples were quantified through extrapolation 
from a standard curve, with purified calf thymus DNA (Worthington 
Biochemical, Freehold, NJ) as the standard. Subsequent data analysis 
incorporated the median value of the three technical replicates for each 
study subject and the time point of testing.
Quantification of miR-122
RNA extraction: Total RNA, including miRNA, was extracted from 400 
µl of serum. RNA extraction was performed using the miRNeasy RNA 
isolation kit (Qiagen, Valencia, CA).
Real-time quantitative reverse-transcription PCR analysis: The expression 
levels of miRNA hsa-miR-122 (miR-122) were quantified using the Taq-
Man miRNA reverse transcription kit and miRNA-specific stem-loop 
primers (Applied Biosystems, Foster City, CA) in a scaled-down (5 µl) 
reverse-transcription reaction as described by Kroh et al.,35 using the 
7900HT instrument (Applied Biosystems). miRNA was quantified using 
absolute quantification via a standard curve, with quantities normalized 
to an exogenous spike-in control derived from Caenorhabditis elegans, 
cel-miR-39.
statistical analysis. Descriptive statistics for liver-function tests and 
biomarkers included the arithmetic mean and SEM. Biomarker values 
were expressed as the multiple of difference from the upper limit of 
normal where data were available for the normal range (with respect 
to ALT, AST, K18, and HMGB1). In the case of biomarkers for which 
the normal range of values in humans has not been established (SDH, 
GLDH, and miR-122), the values were expressed as the multiple of 
increase above the average predose baseline value on day 1. Differences 
between the treatment arms were assessed using two-way analysis of 
variance for which the main effects were treatment type and study 
day. The ALT and AST values for each treatment group were graded 
according to the World Health Organization toxicity criteria (grades 
0–4). Biomarker correlation analyses were performed by calculating 
the Pearson correlation coefficient (σ). Differences between treatment 
groups were deemed significant when P < 0.05.
suPPleMeNtARY MAteRiAl is linked to the online version of the paper at 
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